The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Phase 2 Unknown 88 enrolled Taipei Veterans General Hospital, Taiwan

RandomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to investigate the influence of epidermal growth factor receptor mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.

Timeline

Start: 2005-07
Primary completion: 2015-10
Completion: 2015-10

Outcome

Met primary endpoint

paper Disease control rate (64% vs. 25%; P < 0.001) PMID 26046796 ↗

paper were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. PMID 26046796 ↗

Publications

Wang JP, Wu CY, Yeh YC, Shyr YM, Wu YY, Kuo CY, Hung YP, Chen MH, Lee WP, Luo JC, Chao Y, Li CP. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015 Jul 20;6(20):18162-73. doi: 10.18632/oncotarget.4216.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	100 mg	Oral